Top FDA leaders are projecting enhanced scrutiny of clinical trial data generated outside the US, as lawmakers and industry attempt to respond to concerns about cross-border evidence use. The focus is on ensuring that externally generated research data meets FDA expectations for adequacy and reliability. The move is expected to affect how sponsors structure global trials, assemble submission-ready data packages, and plan for regulatory review and data transfer requirements. For companies building international programs, the message is clear: credibility alone may not be enough if datasets cannot withstand heightened review of methods, sites, and documentation quality.